Keros Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for disorders linked to transforming growth factor-beta protein signaling, is led by an experienced executive. The President and Chief Executive Officer of the company is Dr. Jasbir S. Seehra. Having extensive scientific and leadership background in the biotechnology and pharmaceutical industries, he has guided the organization through key clinical developments, strategic research expansions, and public market milestones. In addition to his responsibilities as CEO, he also serves as the Chair of the Board, overseeing the corporate governance and overarching clinical pipeline strategy aimed at addressing serious neuromuscular and rare diseases.